In short
ranbaxy in norway: The Norwegian Appeals Court ruled that Ranbaxy Laboratories Ltd's generic version of Lipitor did not infringe Pfizer Inc's patents. Ranbaxy says they will now be able to market their products in Norway. Pfizer markets its cholesterol-lowering drug Atorvastatin as Lipitor. The court ruled that three Pfizer patents covering intermediate compounds used to make Atorvastatin, the active ingredients in Liptor, would not be infringed by the sale of a Ranbaxy's generic product in Norway. The two companies have been involved in a patent battle in various markets across the globe.
Related Content
- Action taken report by the District Magistrate and Collector, South 24 Parganas on steps taken to prevent coastal erosion, Sagar Island, West Bengal, 22/02/2025
- Order of the National Green Tribunal regarding damage of an under construction bridge endangering the life of dolphins, Sultanganj, Aguani Ghat, Bhagalpur district, Bihar, 17/02/2025
- Order of the National Green Tribunal regarding unscientific management of the horses plying in Kufri, Himachal Pradesh, 13/02/2025
- Order of the National Green Tribunal regarding encroachment of 6 ponds in village Mundka, Delhi, 02/12/2024
- Report by the Central Groundwater Authority on the presence of arsenic and fluoride in India, 18/11/2024
- Financing the fight against poverty and hunger: mobilising resources for a sustainable development goal reset